IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Susan CHUBINSKAYA et al.

Serial No.: To be assigned

Filed: Concurrently herewith

For: Methods and Compositions Related to Modulators of Annexin and Cartilage Homeostasis

Mail Stop PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

Α,ι	Aanuiia	, TA 2233-1-130							
	INFORMATION DISCLOSURE STATEMENT								
Exa	Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97								
	[] Copies of the references are enclosed [X] Copies of the references were submitted in parent application Serial No. 09/745,989 (37 CFR 1.98(d [] A copy of the International Search Report which issued on International Application No. is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.								
A.	[X] OR	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).							
	[]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).							
B.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.							
	{}	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.							
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).							
C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under \S 1.113, or a notice of allowance under \S 1.311, whichever occurs first, but before the payment of the							

issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [] A duplicate copy of this paper is attached.

Respectfully Submitted,

Michael C. Conger

Attorney of Record Registration No. 43,562

Date: 9/9/03

Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-2474 Facsimile: (919) 483-7988

FORM PTG-1449 INFORMATION DISCLOSURE STATEMENT					ATTORNEY DOCKET NO. SERIAL NO. PU3680US3 T be assigned APPLICANT				
					Susan CHUBINSKAYA et al.				
					ILING DATE		GROUP		
					oncurrently her		GROOI		
			U.S.	PATENT DOC					
Examiner	1							Filing Date	
Initials		Patent Number	Issue Date	<u> </u>	Name	Class	Subclass	If Appropriat	
	1.	5,004,741	04/02/1991	Evans et al.				1	
	2.	5,416,066	05/16/1995	Kaneko et al.					
	├		 					<u> </u>	
	├	+	+	 				ļ	
	\vdash	+	+	 				 	
	+	+	 					 	
				Continue on page					
				ON PATENT D					
		Document	Publication				1	Translatio	
	<u> </u>	Number	Date	C	ountry	Class	Subclass	Yes N	
	 		ļ						
	├	 		 					
	├	+	 	 			ļ		
	├	 	 	 				 	
	+	 	 	 			 		
	_	 	 				 	 	
				Continue on page	-		L		
		OTHER DOCU	MENTS (Includi	ing Author, Tit	le, Journal-Date	, Page Numbe	r, Etc.)		
	3.	Billinghurst et al., "Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage," J. Clin. Invest. 99:1534-1545 (1997).							
	Bohm et al., "Structural and functional comparison of anchorin CII (cartilage annexin V) and r V," Arch Biochem Biophys 314:64-74 (1994).						exin V) and m	uscle annexin	
	5.	Donnelly et al., '	'Annexins in the	secretory pathw	ay," J. Cell. Mole	ec. Life Sci. 53:	533-538 (1997).	
 Donnelly et al., "Annexins in the secretory pathway," J. Cell. Molec. Life Sci. 53:533-538 (1997) Fernandez et al., "The structure of anchorin CII, a collagen binding protein isolated from chondred." 						ocyte			
	L	membrane," Bioi	I. Chem. 263:592	1-5925 (1988).					
 Hofmann et al., "Interactions of benzodiazepine derivatives with annexins," J. Biol. Chem. 273 (1998). 						ol. Chem. 273((5):2885-2894		
8. Huber et al., "Crystal and molecular structure of human annexin V after refinement," J. Mol. Biol. 704 (1992). 9. King et al., "Absence of anchorin CII and impaired collagen binding in the swarm rat chondrosarce Orthop. Res. Soc. Trans. 20:387 (1995). 10. King et al., "Absence of cell-surface annexin V is accompanied by defective collagen matrix bindu swarm rat chondrosarcoma," J. Cell. Biochem. 65:131-144 (1997). 11. Koyano et al., "Collagen and proteoglycan production by bovine fetal and adult chondrocytes unde levels of calcium and zinc ions," Connect Tiss Res 34(3):213-225 (1996). 12. Koyano et al., "Reduced levels of calcium block hypertrophy and degradation of cartilage and stim collagen synthesis in chicken tibial explants," Orthop. Res. Soc. Trans. 21:354 (1996). 13. Koyono et al., "Reduced levels of calcium block hypertrophy and degradation of cartilage and stim collagen synthesis in chicken tibial explants," Orthop. Res. Soc. Trans. 21:354 (1996). 13. Koyono et al., "Quantitative and qualitative analysis of 3H-prolin-labeled protein for the investiga collagen metabolism by rapid filtration in multiwell plates," Bio Techniques 22:706-716 (1997). 14. Liemann et al., "Three-dimensional structure of annexins," J. Cell. Molec. Life Sci. 53:516-521 (195). Mallein-Gerin et al., "Proteoglycan core protein and type II Collagen gene expressions are not correct.							nt," J. Mol. Bio	l. 223:683-	
							rat chondrosa	rcoma,"	
								10.00	
							agen matrix binding in the		
							hondrocytes ur	der low	
							-		
							cartilage and st	imulate	
							igation of th		
							10-710 (1997).	(1997)	
			es during low der						
				Continue on page			()		
XAMINER						DATE CO	NSIDERED		

ATTORNEY DOCKET NO. | SERIAL NO.

INFORMA	TION I	DISCLOSURE ST.	ATEMENT		PU3680US3	To be assigned		
					APPLICANT			
					Susan CHUBINSKA	YA et al.		
					FILING DATE		GROUP	
					Concurrently herew	ith		
			U.S. P	ATENT D	OCUMENTS			
	(T	Filing Date
Examiner Initials	(Patent	Issue Date	1	Name	Class	Subclass	If Appropriate
initials		Number						Appropriate
						·	T	
	_						 	
	_						·	
								
	L		C	ontinue on p	nage	L	I	
					DOCUMENTS			
		Document	Publication		DOCUMENTS			Translation
	i	Number	Date		Country	Class	Subclass	Yes No
		Trumber	Date		Country	Ciass	Subciass	
	 							
						}		L
							_	
	!							
							ļ	L
							ļ	
	L	L		l			<u></u>	L
				ontinue on p				
					Title, Journal-Date, P			
	16.				ation of a Collagen bind	ing Glycop	rotein from Cho	ndrocyte
	17.	Membranes," EM	"Dele ef enche	(1983).	1 000 1	- mantain in	the interestina	-6
	17.	Mollenhauer et al., "Role of anchorin CII, a 31,000-mol-wt membrane protein, in the interaction of chondrocytes with type II collagen." J. Cell Biol. 98:1572-1578 (1984).						
	18.						46 556 (1007)	
	19.	Mollenhauer, "Annexins: what are they good for?," J. Cell. Molec. Life Sci. 53:546-556 (1997). Mollenhauer et al., "," Orthop. Res. Soc. Trans. 23:444 (1998).						
	20.				II (cartilage annexin V)		oung, normal a	dult, and
	l				n. 47(2):209-220 (1999)		C 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	6 :
	21.			ures and m	olecular evolutionary ge	enetics, J.	Сен. могес. Егр	e Sci.
	53:508-515 (1997).							
	22. Raynal et al., "Annexins: the problem of assessing the biological role for a gene family of multifunction calcium-and phospholipid-binding proteins," <i>Biochem. Biophys. Acta</i> 1197:63-93 (1994).							
	23.	Dail and phos	phonpia-billaing	proteins,	ocytes: differential bind	1197:03-9.	(1994).	
	23.						igen and respon	se to
	collagen in suspension culture," Orthop. Res. Soc. Trans. 21:312 (1996). 24. Reutelingsperger et al., "Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and							
	24.				Life Sci. 53:527-532 (1		d inflammation	and
	25						:C- C-1 F2-522	526 (1007)
 Rothhut, "Participation of annexins in protein phosphorylation," J. Cell. Molec. Life Sci. 53:522-526 (Torzilli et al., "Effects of misoprostol and prostaglandin E2 on proteoglycan biosynthesis and loss in 								
	20.							is in
	unloaded and loaded articular cartilage explants," Prostaglandins 52:157-173 (1996). 27. von der Mark et al., "Anchorin CII, a type II collagen binding glycoprotein from chondrocyte membranes"							
	27.					otein from	chondrocyte me	moranes
Ann. NewYork Acad. Sci., 469:214-223 (1985). 28. Von der Mark et al., "Annexin V interactions with collagen," Cell. Mol. Life Sci. 53:539-545 (1997).								05)
	28.	von der Mark et a				oi. Lije Sci.	55:559-545 (19	97).
EVALORES				ontinue on	page	I DAME O	NOTERES	
EXAMINER						DATEC	ONSIDERED	
EVANDER	. Y-1-1	110 -14-41			T. C. C. P	MOED C	O. Daniella, d	
					is in conformance with this form with next con			
Chanon II no	t III COI	normance and not c	onsidered. Inch	ue copy of	uns totti with next con	ununcation	to the applican	<u>. </u>

FORM PTO-1449